

**B Cell antigen D8/17 as a marker of susceptibility to
rheumatic fever in Australians**

and

The sharp end of the needle:

**Rheumatic fever prophylaxis and concepts of care for
Yolngu patients**

A thesis in two parts

Submitted for the degree of Masters of Science (Health Sciences) at

Flinders University, March 2005

Zinta Harrington

Menzies School of Health Research

PO Box 41096 Casuarina

Northern Territory, 0811

Acknowledgements

For part 1, this work was carried out with the assistance of a research scholarship from the Cooperative Research Council of Aboriginal and Tropical Health. The National Heart Foundation of Australia provided funding for the research.

I would like to thank my supervisors Bart Currie and Jonathan Carapetis for their conceptualisation of this study and subsequent guidance and assistance. I am grateful to Kumar Visvanathan and Narelle Skinner for their contribution in the laboratory and enthusiasm for teaching me all I know about laboratory processes. Susan Jacups was helpful in dozens of practical ways at critical moments. Michael Harrington relived his student days by becoming a laboratory assistant in rather humid conditions. Michael Christie's language tuition and assistance in translation was appreciated greatly.

The warmest thanks goes to the people of Galiwin'ku for their willingness to contribute to this project, to Basma Ganalarritj for recruiting people from her home town, Dorothy Bepuka and Dorothy Yungirnya for translating the information sheets and expanding my Yolngu matha vocabulary in order that I could speak fluently about rheumatic fever in Djambarrpuyngu, to Ngalkanbuy Health for facilitating this work, and to *Yalu Marngithinyaraw* (Yalu nurturing centre) for cultural advice and general support.

For part 2, this work was supported by a scholarship provided by the Cooperative Research Council of Aboriginal and Tropical Health. Funding for a co-worker and

project costs was supplied by a grant from the Department of Health and Ageing Regional Health Services Program.

Thank you to my supervisors David Thomas and Bart Currie for generating the question, the means of finding the answers, and all the subsequent encouragement I needed to complete the task.

Joy Bulkanhawuy was indispensable to the completion of this project. Her dedication, professionalism, good advice were all highly valued - *mirrithirr manymak djäma dhuway!*

Members of the *Yalu Marŋgithinyaraw* gave useful advice and support. Thanks to the staff of Ngalkanbuy Health and Marthakal, who were enthusiastic and helpful participants in this study. Michael Christie's assistance with *Yolngu matha* tuition and translation was much appreciated. The patients and families of Galiwin'ku who gave freely of their time and thoughts are deeply appreciated.

And to David and Jahan, who were continually entangled in the whole happy process...

Statement of work undertaken

In part 1, the project was conceptualised by Prof. Bart Currie and Prof. Jonathan Carapetis. I principally performed the data and sample collection, the statistical analysis and interpretation of the D8/17 results. I undertook the D8/17 staining of the community samples, with assistance from Mr Michael Harrington. Kumar Visvanathan and Narelle Skinner stained the samples in the laboratory. The D8/17 flow cytometry was performed by Dr Kumar Visvanathan.

In part 2, I conceptualised and planned this study, with the assistance of my supervisor, David Thomas. My co-researcher, Joy Bulkanhawuy and I developed the interview structure and carried out the interviews in a bilingual fashion. Joy translated the interviews, and then participated in the analysis of the data. I performed the bulk of the analysis and write-up of the data. Joy assisted with the feedback to the community, and the review of the final conclusions.

Declaration

I certify that this thesis does not incorporate without acknowledgement any material previously submitted for a degree or diploma in any university; and that to the best of my knowledge and belief it does not contain any material previously published or written by another person except where due reference is made in the text.

Abstract

Aboriginal Australians have some of the world's highest rates of rheumatic fever. Two approaches to reducing the burden of rheumatic fever are discussed in this thesis. The B cell antigen D8/17 has a strong association with rheumatic heart disease and may be a universal marker of inherited susceptibility to rheumatic fever. Identifying a population at increased risk of rheumatic fever provides an opportunity to focus primary prevention measures. **In part one of the thesis** I evaluate the accuracy of D8/17 as a marker of past rheumatic fever amongst Australians from the Northern Territory. D8/17 levels were measured and compared in patients with acute rheumatic fever, rheumatic heart disease or past rheumatic fever, first-degree relatives and healthy, unrelated controls. The mean percentage of B cells positive for D8/17 was 83.7%, 38.9%, 20.2% and 11.6% respectively. The difference between the groups was significant ($p < 0.0001$). A receiver operator curve analysis indicated that 22.1% of B cells positive for D8/17 was the most accurate cut-off to distinguish patients with acute or past rheumatic fever from healthy subjects. These results indicated that the B cell antigen D8/17 is an accurate marker of past rheumatic fever in Aboriginal Australians and could be a helpful addition to the Jones Criteria for strengthening or excluding a diagnosis of acute rheumatic fever. The intermediate levels of D8/17 expression in the relatives of index cases supports the hypothesis that D8/17 is a marker of an inherited susceptibility to rheumatic fever, although prospective trials are required to provide conclusive proof of this hypothesis.

Non-compliance with secondary prophylaxis was suspected to be the cause of increasing rates of rheumatic fever in the Top End. **In part two of the thesis** I discuss the 'problem of compliance' with respect to Aboriginal patients, and investigate the

factors that affected the delivery and uptake of prophylaxis for rheumatic fever in an Aboriginal community. Patients, relatives and health practitioners were interviewed on the topic of the care of patients with rheumatic heart disease. The data were analysed using the principles of grounded theory.

The main finding was the desire for more personalised care and support for patients with rheumatic heart disease from the community clinic, rather than simple medical care. These ideas crystallised through two Yolngu terms to describe care: *djaka* (to physically care for) and *gunga'yun* (to encourage). Thus even from the outset there was divergence in the focus of the 'consumer'- holistic care - and that of the health-care professional/ researcher – improving the rate of secondary prophylaxis coverage.

With regards to service provision, a significant reason for failure to receive secondary prophylaxis was the differing approaches of urban and community health services, patient mobility, and a differing understanding of the responsibilities of patients and health service providers in the different settings. Other factors pertaining to service provision, such as staff motivation, administrative issues and program coordination affected the uptake of secondary prophylaxis to a lesser extent. With regards to treatment uptake, individual patient factors inhibiting uptake of treatment were apparent in some cases, but treatment refusal was rare. Pain was not found to be a deterrent. No simple relationship was found between treatment compliance and biomedical knowledge of the disease. There was no simple relationship between patient passivity and sense of responsibility that guaranteed compliance.

This study demonstrated that the failure to achieve good uptake of prophylaxis for rheumatic fever related as much to factors of service provision as patient factors and

that providing holistic care within a familiar and supportive framework is important to Yolngu patients. However, there are real difficulties for health services as they are currently structured to meet the expectations of patients and families.

Abbreviations

ALPA	Arnhem Land Progress Association
ARDS	Aboriginal Resource and Development Society
JB	Joy Bulkanhawuy
NT	Northern Territory
PBMC	Purified blood mononuclear cells
RF	Rheumatic fever
RHD	Rheumatic heart disease
ROC	Receiver operator characteristics
SD	Standard deviation
WHO	World Health Organisation
ZH	Zinta Harrington

TABLE OF CONTENTS

PART 1 - B CELL ANTIGEN D8/17 AS A MARKER OF SUSCEPTIBILITY TO RHEUMATIC FEVER IN AUSTRALIANS 1

1	INTRODUCTION	2
1.1	BACKGROUND	2
1.2	THE AIM	4
1.3	THE SCOPE.....	4
2	THE EVIDENCE FOR A GENETIC SUSCEPTIBILITY TO RHEUMATIC FEVER	5
2.1	INTRODUCTION	5
2.2	EPIDEMIOLOGY	5
2.3	GENETICS	9
2.4	BLOOD GROUPS, SECRETOR STATUS AND RHEUMATIC FEVER SUSCEPTIBILITY	10
2.5	RHEUMATIC FEVER AND HLA ASSOCIATIONS.....	10
2.6	EVIDENCE FOR AN INHERITED ALTERED IMMUNE RESPONSE IN RHEUMATIC FEVER	13
2.7	CONCLUSION	15
3	B CELL ANTIGENS AND RHEUMATIC FEVER	16
3.1	PRELIMINARY DISCOVERIES – B CELL ANTIGENS 883 AND 256.....	16
3.2	ANTI D8/17 ANTIBODY	19
3.3	CHOREA AND D8/17	23
3.4	D8/17 EXPRESSION - INHERITED TRAIT OR A REACTIVE STATE?	24
3.5	D8/17 AND OTHER DISEASE PROCESSES: POST-STREPTOCOCCAL REACTIVE ARTHRITIS AND NEUROPSYCHIATRIC DISORDERS.....	28
3.6	D8/17 – CHARACTERISATION, FUNCTION, ROLE IN DISEASE PROCESS	29
3.7	CONCLUSION	30
4	DIAGNOSTIC DIFFICULTIES WITH RHEUMATIC FEVER	31
4.1	INTRODUCTION	31
4.2	LIMITATIONS OF THE JONES CRITERIA FOR THE DIAGNOSIS OF RHEUMATIC FEVER	31
4.3	TOWARDS A DIAGNOSTIC TEST FOR ACUTE RHEUMATIC FEVER	35

4.4	PUBLIC HEALTH IMPLICATIONS OF A SCREENING AND DIAGNOSTIC TEST FOR ACUTE RHEUMATIC FEVER.....	37
4.5	CONCLUSION	38
5	THE SETTING OF THE STUDY	39
5.1	SOCIAL GEOGRAPHY	39
5.2	EPIDEMIOLOGY OF ACUTE RHEUMATIC FEVER AND RHEUMATIC HEART DISEASE IN THE TOP END	40
6	METHODS	42
6.1	OVERVIEW OF THE RESEARCH DESIGN	42
6.2	COMMUNITY SELECTION AND SUBJECT RECRUITMENT	43
6.3	COLLECTION OF DATA, SPECIMENS AND TRANSPORTATION.....	44
6.4	PREPARATION OF PURIFIED BLOOD MONONUCLEAR CELLS	45
6.5	D8/17 ASSAY	45
6.6	STATISTICAL ANALYSIS	47
7	RESULTS	49
7.1	DEMOGRAPHICS.....	49
7.2	RESULTS OF THE D8/17 ASSAY	49
7.3	RECEIVER OPERATOR CURVE ANALYSIS OF D8/17 AS A TEST FOR CURRENT OR PAST RHEUMATIC FEVER.....	52
7.4	TECHNICAL ASPECTS OF THE D8/17 ASSAY.....	54
8	DISCUSSION	56
8.1	SIGNIFICANCE OF THE RESULTS.....	56
8.2	TECHNICAL DIFFICULTIES AND THE HUMAN RESPONSE	60
8.3	FUTURE DIRECTIONS.....	61

**PART 2 - THE SHARP END OF THE NEEDLE: RHEUMATIC FEVER PROPHYLAXIS AND
CONCEPTS OF CARE FOR YOLNGU PATIENTS 63**

9	INTRODUCTION	64
10	PREVENTING RECURRENT RHEUMATIC FEVER	67
10.1	THE EVIDENCE FOR PENICILLIN PROPHYLAXIS FOR ACUTE RHEUMATIC FEVER	67
10.2	RHEUMATIC FEVER CONTROL PROGRAMS	68
10.3	RATES OF PROPHYLAXIS FOR PATIENTS WITH ACUTE RHEUMATIC FEVER	69
10.4	RHD CONTROL PROGRAM IN THE NORTHERN TERRITORY	71
10.5	SUMMARY	74
11	AN OVERVIEW OF ‘COMPLIANCE’	75
11.1	RETHINKING OR ‘FORGETTING’ COMPLIANCE	75
11.2	COMPLIANCE AND ABORIGINAL AUSTRALIANS	78
11.3	COMPLIANCE AND PATIENT EDUCATION	81
11.4	COMPLIANCE WITH RHEUMATIC FEVER PROPHYLAXIS	83
11.4.1	<i>Patient factors</i>	83
11.4.2	<i>Service provision</i>	84
11.4.3	<i>The local situation</i>	85
11.5	SUMMARY	87
12	SETTING THE SCENE	88
12.1	A BRIEF HISTORICAL AND CONTEMPORARY ACCOUNT	88
12.2	THE YOLNGU MEDICAL PARADIGM	92
12.2.1	<i>Illness and disease causation</i>	92
12.2.2	<i>The Yolngu body</i>	94
13	QUALITATIVE RESEARCH METHODS	97
13.1	THE ROLE OF QUALITATIVE RESEARCH IN HEALTH	97
13.2	QUALITATIVE RESEARCH METHODS	98
13.2.1	<i>Introduction to qualitative research</i>	98
13.2.2	<i>Interviews</i>	98

13.2.3	<i>Grounded theory analysis</i>	100
13.2.4	<i>Assessing the quality of qualitative research</i>	101
13.3	CHALLENGES FOR QUALITATIVE RESEARCHERS WORKING WITH ABORIGINAL PEOPLE	103
13.3.1	<i>Consent</i>	103
13.3.2	<i>Intent</i>	104
13.3.3	<i>Communication</i>	105
13.3.4	<i>Cultural mores</i>	106
13.3.5	<i>Choosing a co-worker</i>	108
14	METHODS	109
14.1	THE RESEARCH ORIGINS.....	109
14.2	COMMUNITY SELECTION AND SUPPORT.....	109
14.3	THE RESEARCHERS	110
14.4	SAMPLING	111
14.5	INTERVIEWS	113
14.6	ANALYSIS – GROUNDED THEORY WITH MODIFICATIONS	115
14.7	AUDIT OF PENICILLIN PROPHYLAXIS COVERAGE	116
14.8	COMMUNITY MEETING.....	117
15	PRIMARY RESULTS (OPEN CODING)	117
15.1	STORIES OF GETTING SICK.....	118
15.2	GOOD HEALTH - A COOPERATIVE APPROACH BETWEEN THE PATIENT, THE FAMILY AND THE CLINIC	120
15.2.1	<i>Looking after yourself</i>	120
15.2.2	<i>The role of the family in looking after patients with rheumatic heart disease</i>	124
15.2.3	<i>The role of the clinic in looking after patients with rheumatic heart disease</i>	130
15.3	POOR CARE OF PATIENTS WITH RHEUMATIC HEART DISEASE	135
15.3.1	<i>Patients not looking after their health</i>	135
15.3.2	<i>Families not looking after patients with rheumatic heart disease</i>	140
15.3.3	<i>Problems with the care provided by the clinic</i>	141
15.4	SUGGESTIONS FOR PATIENT CARE	147
15.5	CONCLUSION	154

16	PROCESSES AND CONNECTIONS (AXIAL CODING)	156
16.1	WHY DO SOME PEOPLE MISS THEIR INJECTIONS?	156
16.1.1	<i>Introduction</i>	156
16.1.2	<i>An analysis of the process of health service provision</i>	157
16.1.3	<i>Analysis of the process of treatment uptake</i>	162
16.1.4	<i>Causal and intervening conditions for the process of ‘getting the needles’</i>	169
16.1.5	<i>Audit of Bicillin coverage</i>	170
16.1.6	<i>Discussion of the results of the audit, and correlation with the interview data</i>	172
16.2	KNOWLEDGE AND UNDERSTANDING OF THE DISEASE AND MEDICAL TREATMENTS	175
16.2.1	<i>Patients’ accounts of disease causation and pathology</i>	175
16.2.2	<i>The relationship between knowledge of the disease and ‘getting the needles’</i>	181
16.3	COMMUNICATION	183
16.3.1	<i>Communication about illness between community members</i>	183
16.3.2	<i>Communication between Balanda health staff and Yolngu patients</i>	187
16.4	RESPONSIBILITY AND BLAME	191
16.4.1	<i>Who is responsible for what?</i>	191
16.4.2	<i>Illness and blame</i>	196
16.4.3	<i>A discussion of the intersection of “taking responsibility for health” and “staying well”</i>	198
16.5	RELIGIOUS BELIEFS – CHRISTIANITY AND YOLNGU SPIRITUALITY	199
17	A PRACTICAL OUTCOME? FEEDBACK TO THE COMMUNITY AND THE CONSTITUTION OF A REFORM GROUP	201
18	COMMENTS ON THE RESEARCH PROCESS	205
18.1	RESEARCHER BIAS AND “GOING NATIVE”.....	205
18.2	COMMENTS ON WORKING WITH A YOLNGU CO-RESEARCHER.....	206
18.3	DEFICIENCIES AND DIFFICULTIES IN SAMPLING	208
18.4	COMMENTS ON COMMUNICATION ISSUES PERTAINING TO RESEARCH	210
18.5	TRANSLATION: THE JOYS AND THE DIFFICULTIES.....	212
19	CONCLUSION AND IMPLICATIONS	215

INDEX OF TABLES AND FIGURES

TABLES

TABLE 1 - RISK OF DEVELOPING RF WITH A FAMILY HISTORY OF ‘ACUTE RHEUMATISM’ IN A FIRST- DEGREE RELATIVE, CASE-CONTROL STUDY	6
TABLE 2 - THE RISK OF DEVELOPING RF WITH A HISTORY IN EITHER PARENT, COHORT STUDY	7
TABLE 3 - THE CONCORDANCE OF RF IN TWINS.....	8
TABLE 4 - RELATIONSHIP BETWEEN HLA TYPE AND RF	12
TABLE 5 - COMPARISON OF STUDIES RELATING D8/17 EXPRESSION AND RF OR RHD.....	21
TABLE 6 - COMPARISON OF STUDIES RELATING D8/17 EXPRESSION AND RF OR RHD.....	24
TABLE 7 - PERCENTAGE OF B CELLS POSITIVE FOR D8/17 ACCORDING TO CATEGORY	26
TABLE 8 - THE JONES CRITERIA	32
TABLE 9 - COMMON DIFFERENTIAL DIAGNOSES OF ACUTE RHEUMATIC FEVER	35
TABLE 10 - TOP END BASIC DEMOGRAPHICS.....	39
TABLE 11 - MEDIAN AGE AT DEATH OF AUSTRALIANS IN 2002 (YEARS).....	39
TABLE 12 - RESEARCH SUBJECTS.....	49
TABLE 13 – MEAN (SD) PERCENTAGE OF B CELLS POSITIVE FOR D8/17 ACCORDING TO CATEGORY	50
TABLE 14 - DIFFERENCE OF THE MEAN OF B CELLS POSITIVE FOR D8/17, BY CATEGORY.....	51
TABLE 15 - SENSITIVITY AND SPECIFICITY OF D8/17 FOR PAST OR CURRENT RF AT VARIOUS CUT POINTS	53
TABLE 15 - YOLNGU PERCEPTIONS OF THE CAUSE OF DISEASE.....	94
TABLE 16 - GLOSSARY OF TERMS USED IN GROUNDED THEORY	101
TABLE 17 - NUMBERS OF PERSONS INTERVIEWED ACCORDING TO CATEGORY AND SEX	112
TABLE 18 - MATRIX FOR THE PROCESS OF ‘GETTING THE NEEDLES’	161
TABLE 19 - FACILITATORS AND IMPEDIMENTS TO "GETTING THE NEEDLES"	170
TABLE 20 - PERCEPTIONS OF THE RESPONSIBILITIES OF THE PATIENT, THE FAMILY AND THE CLINIC.....	191

FIGURES

FIGURE 1 - SERUM 883 (OR ITS CLONE 83S19.23) AS A MARKER OF PAST RHEUMATIC FEVER OR RHEUMATIC HEART DISEASE.....	17
FIGURE 2 - D8/17 AS A MARKER OF PAST RHEUMATIC FEVER OR RHEUMATIC HEART DISEASE.....	22
FIGURE 3 – COMPARISON OF D8/17 WITH INDIAN ANTIBODIES FOR IDENTIFYING RHEUMATIC FEVER/ RHEUMATIC HEART DISEASE.....	23
FIGURE 4 - ANNUAL INCIDENCE OF RHEUMATIC FEVER IN SELECTED POPULATIONS.....	40
FIGURE 5 - POINT PREVALENCE OF RHEUMATIC HEART DISEASE IN SELECTED POPULATIONS	41
FIGURE 6- RESEARCH DESIGN.....	43
FIGURE 7 – METHOD OF STAINING FOR D8/17 ASSAY	46
FIGURE 8 - PERCENT B CELLS STAINING POSITIVE ANALYSED BY CLINICAL CATEGORY	51
FIGURE 9 - RECEIVER OPERATOR CHARACTERISTICS CURVE FOR D8/17 AS A TEST FOR RHEUMATIC FEVER OR PAST RHEUMATIC FEVER	53
FIGURE 10 - COMPARISON OF IMMEDIATE VERSUS DELAYED STAINING FOR D8/17 ANALYSIS	54
FIGURE 11 - COMPARISON OF D8/17 ANALYSIS ON FRESH WHOLE BLOOD VERSUS FROZEN PBMCs	55
FIGURE 12 - WHO PROJECT FOR THE CONTROL OF RHEUMATIC FEVER: RANGES AND MEANS OF PENICILLIN PROPHYLAXIS BY WORLD REGION.....	70
FIGURE 13 - CASES OF ACUTE RHEUMATIC FEVER IN THE TOP END.....	72
FIGURE 14 - RECURRENT RHEUMATIC FEVER AS A PERCENTAGE OF RHEUMATIC FEVER.....	73
FIGURE 15 - INNER AND OUTER CIRCLES OF CARE.....	165
FIGURE 16 - DIAGRAMMATIC REPRESENTATION OF THE PROCESS OF GETTING THE INJECTIONS	168
FIGURE 17 - PERCENT OF PROPHYLACTIC INJECTIONS ADMINISTERED TO PATIENTS IN GALIWIN'KU BY MONTH.....	171
FIGURE 18 - PERCENT OF PROPHYLACTIC INJECTIONS RECEIVED BY EACH PATIENT	172